Cargando…
Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors
Background Plasma cell disorders (PCD) are at risk of inadequate immune responses to COVID-19 vaccines due to recognised humoral and cellular immune dysfunction which is multi-factorial and related to host and disease factors. With an estimated risk of 33% mortality from contracting COVID-19 in this...
Autores principales: | Chan, Wei Yee, Howells, Lara, Wilson, William, Sanchez, Emilie, Ainley, Louise, Chavda, Selina J, Dowling, Emma, Correia, Nuno, Lecat, Catherine SY, McMillan, Annabel, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Lee, Lydia, Sive, Jonathan, Kyriakou, Charalampia, Wechalekar, Ashutosh D., Popat, Rakesh, Rabin, Neil K, Nastouli, Eleni, Yong, Kwee, Xu, Ke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701903/ http://dx.doi.org/10.1182/blood-2021-149027 |
Ejemplares similares
-
OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines
por: Chan, Wei Yee, et al.
Publicado: (2021) -
CD19+ B Lymphocytes Are Predictive for Anti-Sars-Cov-2 Vaccination Response in Multiple Myeloma Patients
por: Ghandili, Susanne, et al.
Publicado: (2021) -
COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
por: Branagan, Andrew R., et al.
Publicado: (2021) -
Inadequate Sars-Cov-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study
por: Fillmore, Nathanael R, et al.
Publicado: (2021) -
Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients
por: Stampfer, Samuel D., et al.
Publicado: (2021)